Legionella Infections¶
Chapter 164 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Legionella species cause two primary diseases: Legionnaires' disease (atypical pneumonia) and Pontiac fever (self-limiting flu-like illness).
- Legionnaires' disease is responsible for >50% of waterborne outbreaks in the U.S., with L. pneumophila serotype 1 being the most common pathogen.
- Diagnosis requires laboratory confirmation due to nonspecific symptoms; urinary antigen testing is rapid but limited to L. pneumophila serotype 1.
- Treatment guidelines recommend fluoroquinolones (levofloxacin, moxifloxacin) or macrolides (azithromycin) for severe cases; dual therapy may be used in immunocompromised patients.
- Prevention focuses on water system management to prevent Legionella growth in premise plumbing and healthcare facilities.
1. DEFINITION & OVERVIEW¶
Legionella species cause two primary human diseases: Legionnaires' disease (atypical pneumonia) and Pontiac fever (self-limiting flu-like illness). These infections are waterborne and linked to aerosolized organisms from contaminated water systems. Legionella pneumonia is the most common manifestation, while Pontiac fever is a milder, non-pulmonary illness.
Table 164-2: Clinical and Epidemiologic Features¶
| FEATURE | LEGIONELLA PNEUMONIA | PONTIAC FEVER |
|---|---|---|
| Incubation period | 2–10 daysa | 24–72 h |
| Common symptoms | Abdominal or chest pain, confusion, diarrhea, fever, myalgias, nausea/vomiting, shortness of breath | Cough, diarrhea, fatigue, fever, headache, myalgias, nausea/vomiting, vertigo |
| Risk factors | Age >40 years, male, smoker, immunosuppressed, chronic lung disease, organ dysfunction | Age >40 years, male, smoker, immunosuppressed, neurologic disease, chronic lung disease |
| Attack rate among exposed individuals | ~5%c | ~90% |
| ICU admission rate | 30–50% | Extremely low |
| Case-fatality rate | 10% | Extremely low |
1.1 Pathogenesis¶
Legionella species are aerobic gram-negative bacteria that thrive in aquatic environments and biofilms. They replicate intracellularly within amoebae and human macrophages, evading immune defenses through mechanisms like Legionella-containing vacuoles and cytokine receptor downregulation. L. pneumophila serotype 1 is most cytopathogenic and associated with severe disease.
1.2 Clinical Spectrum¶
Legionella infections range from mild self-limiting illness (Pontiac fever) to severe pneumonia with high mortality in immunocompromised patients. Extrapulmonary manifestations include endocarditis, septic arthritis, and meningitis, though rare.
2. EPIDEMIOLOGY¶
Legionella species cause >50% of waterborne outbreaks in the U.S. and >10% of drinking water-related disease. Incidence is 2–3 cases per 100,000 persons, but higher in other regions. L. pneumophila serotype 1 accounts for >80% of cases, though non-pneumophila species (e.g., L. longbeachae) are increasingly implicated in outbreaks, especially in Australia/New Zealand. Underreporting is common due to limited testing in community-acquired pneumonia cases.
Table 164-1: Common Source Outbreaks¶
| SITE | YEAR | ORGANISMa | REPORTED SOURCE(S) | CASES |
|---|---|---|---|---|
| Hotelb | 2012 | L. pneumophila serotype 1 | Potable water, fountain, spa | 85 (29 suspect) |
| Communityd | 2014 | L. pneumophila serotype 1 | Cooling tower | 334 cases |
| Long-term care facilityf | 2015 | L. pneumophila | Potable water | 74 cases |
| Communityg | 2015 | L. pneumophila | Hotel cooling towers | 128 cases |
| Hospitalh | 2018 | L. pneumophila serotype 1 | Potable water, showers | 13 cases |
| Communityj | 2019 | L. pneumophilak | Hot-tub display | 141 cases |
| Communityl | 2022 | L. pneumophila serotype 1 | Cooling tower | 17 cases |
2.1 Seasonality and Climate¶
Legionella disease incidence peaks in summer/fall with increased humidity and temperature. Seasonal storms and plumbing disruptions can contaminate water systems, increasing exposure risk. Climate change and aging infrastructure may contribute to rising cases.
2.2 Outbreak Sources¶
Common sources include cooling towers, hot tubs, plumbing systems, and hospital water supplies. Outbreaks often involve aerosolized droplets from water systems, with 5–30% of households potentially harboring Legionella species.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Legionella species are ubiquitous in aquatic environments, thriving in biofilms and amoebae. They replicate intracellularly in human macrophages, evading immune defenses. L. pneumophila serotype 1 is most pathogenic, while non-pneumophila species (e.g., L. longbeachae) are increasingly associated with outbreaks. Immunosuppression, chronic lung disease, and smoking increase susceptibility.
3.1 Virulence Mechanisms¶
Legionella uses Legionella-containing vacuoles, cytokine receptor downregulation, and inhibition of host protein synthesis to evade immune responses. These mechanisms contribute to its ability to cause severe pneumonia and extrapulmonary infections.
3.2 Host Factors¶
Immunosuppression (e.g., cancer, transplant recipients), chronic lung disease, and smoking increase risk. Elderly patients and those with renal/hepatic dysfunction are at higher risk for severe disease.
4. CLINICAL FEATURES¶
Legionnaires' disease presents as atypical pneumonia with fever, myalgias, cough, and respiratory distress. Pontiac fever is a self-limiting flu-like illness with fever, headache, and myalgias. Extrapulmonary manifestations include endocarditis, septic arthritis, and meningitis, though rare.
4.1 Legionnaires' Disease¶
Classically presents with rales, rhonchi, and pulmonary consolidation. Severe cases may require ICU admission with high mortality (10% overall, 30–50% in immunocompromised patients).
4.2 Pontiac Fever¶
Mild, self-limiting illness with fever, headache, and myalgias. No pneumonia, and no specific treatment required. Symptoms resolve within 3–5 days.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include other atypical pneumonias (e.g., Chlamydia, Mycoplasma), viral pneumonia, and bacterial pneumonia. Pontiac fever must be distinguished from influenza and other viral illnesses.
5.1 Atypical Pneumonia¶
Legionella pneumonia overlaps with Chlamydia and Mycoplasma infections in clinical presentation but is distinguished by specific diagnostic tests (e.g., urinary antigen, PCR).
5.2 Non-Infectious Causes¶
Pulmonary embolism, heart failure, and interstitial lung disease may mimic Legionella pneumonia. Serologic testing and imaging are critical for differentiation.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires laboratory confirmation due to nonspecific symptoms. Urinary antigen testing (L. pneumophila serotype 1), serology, and molecular methods (PCR) are key. Radiographic findings include focal infiltrates or consolidations on chest X-ray/CT.
Table 164-3: Legionella Treatment Options¶
| DISEASE | DISEASE SEVERITY | TREATMENT |
|---|---|---|
| Pontiac fever | MILD | None |
| Legionella pneumonia | MILD | Fluoroquinolone (levofloxacin 750 mg PO daily) or macrolide (azithromycin 500 mg PO daily) |
| DISEASE | DISEASE SEVERITY | TREATMENT |
|---|---|---|
| Legionella pneumonia | MODERATE/SEVEREa,b | Fluoroquinolone IV (levofloxacin 750 mg IV daily) or macrolide IV (clarithromycin 400 mg IV twice daily) |
6.1 Diagnostic Tests¶
Urinary antigen testing is rapid but limited to L. pneumophila serotype 1. Serology (acute/convalescent titers) and PCR (for lower respiratory specimens) are more comprehensive. DFA testing of sputum has lower sensitivity.
6.2 Imaging¶
Chest X-ray shows focal infiltrates in lower lobes; CT reveals ground-glass opacities and consolidations. Immunocompromised patients may present with atypical findings like nodules or cavitations.
7. MANAGEMENT & TREATMENT¶
Antibiotics targeting intracellular pathogens are required for Legionnaires' disease. Macrolides (azithromycin) and fluoroquinolones (levofloxacin) are first-line. Dual therapy may be used in immunocompromised patients. Pontiac fever requires no specific treatment.
7.1 Antibiotic Therapy¶
First-line agents: azithromycin (oral or IV), levofloxacin (oral or IV). Dual therapy with doxycycline or rifampin may be used in severe cases or immunocompromised patients. Avoid macrolides in patients with allergies.
7.2 Supportive Care¶
Oxygen, ICU admission for severe cases, and monitoring for complications (e.g., ARDS, sepsis). Duration of treatment is 5–14 days for community-acquired pneumonia, longer for severe or immunocompromised patients.
8. PROGNOSIS & COMPLICATIONS¶
Case-fatality rate is ~10% for Legionnaires' disease, rising to 25–50% in immunocompromised patients. Complications include respiratory failure, sepsis, and multi-organ failure. Long-term sequelae include recurrent pneumonia and renal failure in survivors.
8.1 Mortality¶
Mortality is higher in ICU patients, those with comorbidities, and immunocompromised hosts. Delayed treatment increases mortality by ~3-fold.
8.2 Long-Term Outcomes¶
Over 25% of survivors have ongoing complications, including recurrent hospitalizations, renal failure, and respiratory issues. Early diagnosis and treatment improve outcomes.
9. SPECIAL CONSIDERATIONS¶
Immunocompromised patients (e.g., transplant recipients, cancer patients) are at higher risk for severe disease. Smoking, chronic lung disease, and renal/hepatic dysfunction increase susceptibility. Pregnancy and pediatric cases are rare but require careful management.
9.1 Healthcare-Associated Infections¶
Nosocomial Legionella infections are rare but linked to contaminated water systems. Outbreaks in healthcare facilities require immediate investigation and water system remediation.
9.2 Special Populations¶
Pregnancy and pediatrics: Rare but possible. Elderly patients and those with chronic illnesses have higher morbidity and mortality. Smoking cessation is a key preventive measure.
10. KEY POINTS & CLINICAL PEARLS¶
- Legionella infections are waterborne and linked to aerosolized organisms from contaminated water systems.
- Urinary antigen testing is rapid but limited to L. pneumophila serotype 1.
- Fluoroquinolones and macrolides are first-line treatments for Legionnaires' disease.
- Pontiac fever is a self-limiting illness requiring no specific treatment.
- Prevention focuses on water system management to prevent Legionella growth in premise plumbing and healthcare facilities.